Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies
A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 262 participants.
Also called NCT04670809
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 262 participants
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
- Registry
-
NCT04670809
-
- Other papers using this trial's data
- Efficacy and safety of clevidipine emulsion injection compared with nicardipine in patients with hypertensive emergencies: a randomized, single-blind, positive-parallel-controlled, phase III clinical trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT04670809. Randomized; single masking; primary purpose treatment. Start 2020-07-27 (actual); primary completion 2021-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy Study of Clevidipine Butyrate Injection in Hypertensive Emergencies
- Condition
- Hypertensive Emergency
- Intervention (Drug)
- Clevidipine Butyrate Injection
- Intervention (Drug)
- Ncardipine Hydrochloride Injection
- Lead sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Record details
- Record id
cardio:ct-nct04670809- Content hash
c72472d8d1ef0c5d03ad092c5516c774f31252849f8a3318eab4ebc7c9cdb6e7